Acute toxicity is a dose-limiting factor for intravenous polymyxin B: A safety and pharmacokinetic study in healthy Chinese subjects

• Published in: The Journal of infection Vol. 82; no. 2; pp. 207 - 215
• Main Authors: Liu, Xiaofen, Chen, Yuancheng, Yang, Haijing, Li, Jian, Yu, Jicheng, Yu, Zhenwei, Cao, Guoying, Wu, Xiaojie, Wang, Yu, Wu, Hailan, Fan, Yaxin, Wang, Jingjing, Wu, Jufang, Jin, Yi, Guo, Beining, Hu, Jiali, Bian, Xingchen, Li, Xin, Zhang, Jing
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.02.2021
• Subjects: Administration, Intravenous; Anti-Bacterial Agents - adverse effects; China; Female; Healthy Volunteers; Humans; Male; Neurotoxicity; Pharmacokinetics; Polymyxin; Polymyxin B - adverse effects; Safety; Urinary recovery; China; Neurotoxicity; Safety; Polymyxin; Pharmacokinetics; Urinary recovery

•A single-dose (at 0.75 or 1.5 mg/kg) clinical trial of polymyxin B was firstly conducted in healthy Chinese subjects.•Acute toxicity (including neurotoxicity) is a dose-limiting factor for intravenous polymyxin B.•It’s important to monitor the adverse reactions and the polymyxin B daily dose should...